Regenerative Medicine 101
Dezawa Muse cells are a naturally occurring class of pluripotent stem cells discovered in 2010. This guide explains what they are, where they come from, and why they're considered a different category from conventional stem cell therapies.
The Science
From S1P-S1PR2 homing to spontaneous differentiation through phagocytosis, this article walks through the five published mechanisms by which Dezawa Muse cells are studied to support tissue repair.
Safety
Tumor risk, immune rejection, long-term safety data, and the gene expression profile (Let-7↑ / Lin28↓) that researchers cite as a built-in safety mechanism. A direct review of the published evidence.
Applications
Cardiovascular, orthopedic, neurological, and organ-system applications under investigation - with clinical trial identifiers and a clear distinction between research stages and approved indications.
Comparisons
Pluripotency without tumor risk, immune privilege, and active migration to injury sites. A side-by-side comparison of Muse cells, MSCs, iPSCs, and embryonic stem cells.
Regulatory
What "FDA approved" actually means for cell therapies, where Dezawa Muse cells sit in the U.S. and Japanese regulatory landscape, and what physicians can legally offer in 2026.
Cost & Access
Investment ranges, what drives the cost, financing options, HSA/FSA considerations, and how the cost compares to ongoing pain management or surgical alternatives.
History & Discovery
The 2010 discovery at Tohoku University, Professor Mari Dezawa's research career, and how independent researchers worldwide have validated and expanded on her findings.
Choosing a Provider
Source verification, SSEA-3+ testing, certificate of authenticity, and the questions to ask any clinic claiming to offer "stem cell" or "Muse cell" therapy.